Epilepsia Open publishes results of post hoc data analysis of FINTEPLA® (fenfluramine) in patients with Lennox-Gastaut syndrome
UCB said EpilepsiaOpen published post hoc results from an open-label extension of FINTEPLA (fenfluramine) in Lennox-Gastaut syndrome. In 247 patients continuing from a Phase 3 trial, median seizure reductions ranged from -32.1% at Month 1 to about -48% by Months 4-6, with CGI-I global improvements by Month 12. Safety matched known effects, with TEAEs highest at initiation and declining over time. UCB reported 2025 revenue of €7.7 billion.
How this was made
The 30-second read
Why it matters
UCB highlights rapid seizure-frequency reductions and improvements in global functioning (CGI-I) after starting FINTEPLA in an open-label extension, with a safety profile described as consistent with known data and improving tolerability over time.
Market read
Provides quantified trajectory metrics (Month 1 and Month 12) for seizure reduction and CGI-I global functioning in LGS patients, but remains post hoc and therefore less likely to drive major repricing without additional primary evidence.
What to watch
The article does not provide new regulatory actions, label changes, or primary endpoint results, so any valuation impact likely depends on how the market already prices FINTEPLA’s OLE trajectory.
Background
FINTEPLA (fenfluramine) is FDA-approved for seizures associated with Lennox-Gastaut syndrome and Dravet syndrome in patients 2 years and older.
Ticker impact
UCB announced EpilepsiaOpen published post hoc FINTEPLA (fenfluramine) trajectory results in Lennox-Gastaut syndrome, including seizure and CGI-I improvements plus safety/tolerability details.
Near-term impact likely limited to sentiment, with more durable repricing requiring prospective/primary data or regulatory/commercial milestones.
The article provides new quantified trajectory metrics (Month 1 and Month 12) and safety pattern commentary, but it is a post hoc analysis with no new efficacy claims beyond what the underlying OLE data already implies.
Market effects
Adds incremental evidence points for fenfluramine’s positioning in rare epilepsy, potentially supporting sentiment around DEE/LGS treatment pipelines.
Primarily affects European biopharma sentiment tied to UCB’s CNS/epilepsy franchise.
Moderate global relevance for rare epilepsy investors, but not a broad sector catalyst.
Counterpoint
Because the analysis is post hoc and explicitly cautions against efficacy conclusions, traders may discount it as marketing-supportive rather than decision-grade evidence.
Key entities
- drugFINTEPLA (fenfluramine)
FDA-approved therapy for LGS and DS; subject of the post hoc trajectory analysis.
- indicationLennox-Gastaut syndrome (LGS)
Rare, severe developmental and epileptic encephalopathy; patient population in the analysis.
- publicationEpilepsiaOpen
Journal/platform where the post hoc analysis was published.
- companyUCB
Announced the publication and provided summarized results and safety/tolerability commentary.
